Page last updated: 2024-08-24
rubitecan and betadex
rubitecan has been researched along with betadex in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fang, X; Jiang, Y; Sha, X; Zhang, W | 1 |
| Chen, Y; Fang, X; Gu, J; Jiang, X; Jiang, Y; Law, K; Sha, X; Xin, H; Zhang, W | 1 |
Other Studies
2 other study(ies) available for rubitecan and betadex
| Article | Year |
|---|---|
Complex of 9-nitro-camptothecin in hydroxypropyl-beta-cyclodextrin: in vitro and in vivo evaluation.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Area Under Curve; beta-Cyclodextrins; Camptothecin; Drug Evaluation, Preclinical; Drug Stability; Freeze Drying; Half-Life; Hydrogen-Ion Concentration; Hydrolysis; Male; Rats; Rats, Sprague-Dawley; Solubility; Temperature | 2010 |
Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; beta-Cyclodextrins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compounding; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred ICR; Sarcoma 180; Toxicity Tests, Chronic; Xenograft Model Antitumor Assays | 2011 |